Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| erythroblast | 5 studies | 34% ± 14% | |
| endothelial cell | 5 studies | 21% ± 4% | |
| epithelial cell | 5 studies | 35% ± 15% | |
| hematopoietic precursor cell | 3 studies | 25% ± 6% | |
| basal cell | 3 studies | 29% ± 9% | |
| dendritic cell | 3 studies | 21% ± 2% | |
| intestinal crypt stem cell | 3 studies | 22% ± 6% | |
| erythrocyte | 3 studies | 34% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 33% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| intestine | 100% | 952.88 | 966 / 966 | 100% | 67.56 | 527 / 527 |
| ovary | 100% | 877.39 | 180 / 180 | 100% | 46.29 | 430 / 430 |
| stomach | 100% | 736.86 | 359 / 359 | 100% | 60.78 | 286 / 286 |
| uterus | 100% | 877.32 | 170 / 170 | 100% | 70.93 | 459 / 459 |
| esophagus | 100% | 1003.20 | 1444 / 1445 | 100% | 42.75 | 183 / 183 |
| thymus | 100% | 1132.98 | 653 / 653 | 100% | 43.82 | 604 / 605 |
| bladder | 100% | 996.29 | 21 / 21 | 100% | 56.22 | 503 / 504 |
| skin | 100% | 1431.64 | 1809 / 1809 | 100% | 53.21 | 471 / 472 |
| breast | 100% | 994.19 | 459 / 459 | 100% | 42.71 | 1113 / 1118 |
| liver | 100% | 950.07 | 226 / 226 | 100% | 26.84 | 404 / 406 |
| pancreas | 100% | 754.15 | 328 / 328 | 99% | 28.17 | 177 / 178 |
| prostate | 100% | 791.96 | 244 / 245 | 99% | 25.96 | 497 / 502 |
| brain | 98% | 743.56 | 2602 / 2642 | 100% | 29.16 | 705 / 705 |
| lung | 98% | 796.74 | 569 / 578 | 100% | 42.39 | 1155 / 1155 |
| adrenal gland | 100% | 1254.97 | 258 / 258 | 98% | 32.42 | 225 / 230 |
| kidney | 100% | 916.00 | 89 / 89 | 97% | 22.26 | 874 / 901 |
| adipose | 100% | 993.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 52.95 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 55.49 | 29 / 29 |
| spleen | 100% | 812.59 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 59.45 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 33.45 | 1 / 1 |
| blood vessel | 100% | 1070.45 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 906.40 | 801 / 803 | 0% | 0 | 0 / 0 |
| heart | 93% | 554.29 | 800 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 52% | 757.04 | 486 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0080129 | Biological process | proteasome core complex assembly |
| GO_0021930 | Biological process | cerebellar granule cell precursor proliferation |
| GO_0051131 | Biological process | chaperone-mediated protein complex assembly |
| GO_0101031 | Cellular component | protein folding chaperone complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0070628 | Molecular function | proteasome binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0060090 | Molecular function | molecular adaptor activity |
| Gene name | PSMG1 |
| Protein name | Proteasome assembly chaperone 1 (PAC-1) (Chromosome 21 leucine-rich protein) (C21-LRP) (Down syndrome critical region protein 2) Proteasome assembly chaperone 1 |
| Synonyms | DSCR2 PAC1 C21LRP |
| Description | FUNCTION: Chaperone protein which promotes assembly of the 20S proteasome as part of a heterodimer with PSMG2. The PSMG1-PSMG2 heterodimer binds to the PSMA5 and PSMA7 proteasome subunits, promotes assembly of the proteasome alpha subunits into the heteroheptameric alpha ring and prevents alpha ring dimerization. . |
| Accessions | ENST00000331573.8 [O95456-1] ENST00000380900.2 [O95456-2] ENST00000411828.5 F8WBH7 H7C3B4 ENST00000431628.1 O95456 |